Increased Expression of CD95 in CD4+ Effector Memory T Cells Promotes Th17 Response in Patients with Myasthenia Gravis

Huang, Xiaoyu; Zhu, Jie; Liu, Tan; Li, Fengzhan; Yang, Tingting; Li, Hao; Chen, Fei; Zhang, Yong; Wang, Yu‐Zhong; Fu, Lei; Xiao, Chengshan; Geng, Deqin

doi:10.1007/s11481-021-10030-7

Cited by 3 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We consecutively recruited 110 MG patients from the affiliated hospital of Xuzhou medical university from November 2021 to February 2023. The sample size was referred to our and other team's previous researches (Huang et al, 2022; Liu et al, 2021; Zhang et al, 2016). The diagnosis of MG was strictly made by experienced neurologists on the basis of typical signs of fluctuating skeletal muscle weakness, and at least one positive result from the criteria followed: (1) presence of serum anti‐acetylcholine receptor antibodies (AChR‐Abs) or muscle‐specific receptor tyrosine kinase antibodies (MuSK‐Abs); (2) reduced U‐shaped response at repetitive nerve stimulation; (3) positive response to neostigmine.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Plasma C18:0‐ceramide is a novel potential biomarker for disease severity in myasthenia gravis

Zhang

Huang

et al. 2023

Journal of Neurochemistry

View full text Add to dashboard Cite

Myasthenia gravis (MG) is an antibody‐mediated autoimmune disorder characterized by fluctuation of fatigue and weakness of muscle. Due to the heterogeneity of the course of MG, available biomarkers for prognostic prediction are urgently needed. Ceramide (Cer) was reported to participate in immune regulation and many autoimmune diseases, but its effects on MG remain undefined. This study aimed to investigate the ceramides expression levels in MG patients and their potential as novel biomarkers of disease severity. Levels of plasma ceramides were determined by ultra performance liquid chromatography–tandem mass spectrometry (UPLC‐MS/MS). Severity of disease was assessed by quantitative MG scores (QMGs), MG‐specific activities of daily living scale (MG‐ADLs) and 15‐item MG quality of Life (MG‐QOL15). The concentrations of serum interleukin‐1β (IL‐1β), IL‐6, IL‐17A, and IL‐21 were determined by enzyme‐linked immunosorbent assay (ELISA), and the proportions of circulating memory B cells and plasmablasts were detected by flow‐cytometry assay. Four plasma ceramides levels we studied were detected higher in MG patients. And three of them (C16:0‐Cer, C18:0‐Cer, and C24:0‐Cer) were positively associated with QMGs. In addition, receiver operating characteristic (ROC) analysis suggested that plasma ceramides have a good ability of differentiating MG from HCs. Importantly, only C18:0‐Cer was shown to be positively associated with the concentration of serum IL and circulating memory B cells, and the decrease in plasma C18:0‐Cer paralleled the clinical improvement of patients with MG. All together, our data suggest that ceramides may play an important role in the immunopathological mechanism of MG, and C18:0‐Cer has the potential to be a novel biomarker for disease severity in MG.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Study Populationmentioning

confidence: 99%